Navigation Links
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Date:5/13/2008

, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's business model, strategic plans for its business, product candidates and technology, (vi) ChemoCentryx's ability to maintain and establish collaborations or obtain additional government grant funding, (vii) ChemoCentryx's estimates of its expenses, future revenues, capital requirements and its needs for additional financing, (viii) the timing or likelihood of regulatory filings and approvals, (ix) the availability of corporate partners, (x) the scope of protection ChemoCentryx is able to establish and maintain for intellectual property rights covering its product candidates and technology, (xi) the impact of competitive products and technological changes, (xii) the availability of capital and the cost of capital, (xiii) ChemoCentryx's financial performance, (xiv) developments relating to ChemoCentryx's competitors and other vagaries in the biotechnology industry and (xv) other risks.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChemoCentryx undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Go Healthy Initiates Additional Clinical Tests on Cholesterade
2. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
5. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... quarter 2014 financial results will be released on Thursday, ... a conference call and live webcast at 1:30 p.m. ...
(Date:10/30/2014)... 30, 2014 Extensiv ... Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ... Säuglingen und Kleinkindern. Der bisher übliche Umgang ... der Babys bzw. deren stillenden Mütter Milchproteine ... sich bei einer beträchtlichen Anzahl von Kindern ...
(Date:10/30/2014)... , Oct. 30, 2014 Today, DripDrop, ... announced that it was awarded a two-year contract, ... services company that serves the more than 100,000 ... Hospital Association and Provista.  DripDrop ... feedback from member hospitals who attended the recent ...
Breaking Medicine Technology:BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4
... MEETING, Pa., Feb. 16, 2012 ECRI Institute ... approaches to improving patient care, has released CT ... to give hospital leaders an at-a-glance overview of the ... popular makes and models, to average pricing, and most ...
... a leading pharmaceutical CRO, announced today that Robert Gwozdz, ... efforts.  According to Mark Mitchnick, the company,s CEO, "PSI ... across many dosage forms and drug types.  For instance, ... molecules of which about 80% fall into BCS II.  ...
Cached Medicine Technology:ECRI Institute Guides Hospital Decision-Makers in the Purchase of CT Scanning Systems 2ECRI Institute Guides Hospital Decision-Makers in the Purchase of CT Scanning Systems 3Particle Sciences Hires Robert Gwozdz to Head Oral Formulation 2
(Date:10/30/2014)... Global prebiotics market is expected to ... new study by Grand View Research, Inc. Positive outlook ... and fat free products owing to increased concerns over ... over the forecast period. , View full report with ... beverage was the largest application segment with market volume ...
(Date:10/30/2014)... South Carolina (PRWEB) October 30, 2014 ... and should be more vigorously exercised to help maintain ... recently authored the book ‘Dementia Express: Lose Your Memory ... book uses counterintuitive reasoning and sometimes conflicting attitudes to ... course for the mind, a reader must decipher the ...
(Date:10/30/2014)... Sound Telecom, a leader in the call center industry, just ... they wonder, “Should I use an answering service?” The graphic ... a series of yes or no questions that ultimately ends ... many considerations and scenarios that come into play when deciding ... This decision infographic serves as a bit of a map ...
(Date:10/30/2014)... Amy Norton HealthDay ... Exposure to a common plastics, chemical during pregnancy may have ... hints. Researchers found that baby boys born to moms ... have a shorter anogenital distance -- the space between the ... and it,s considered a marker of exposure to androgens ("male" ...
(Date:10/30/2014)... -- Eating a low-carb, high-fat diet could help control ... research. A review of five studies found ... on foods like bacon, eggs, heavy cream, butter, fish ... whose condition doesn,t improve with medication. "We need ... epilepsy whose seizures are not stopped by medications," study ...
Breaking Medicine News(10 mins):Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... NHS Hospital Trusts on Sunday, thankfully no patient data ... in charge of the IT services in NHS conveyed ... were interrupted due to the failure of equipment that ... will be maintained till ,the system is restored. ...
... problems may face the risk of several underlying medical complications, ... ,A team from the New England Research Institute in Massachusetts ... over 15 years and looked at markers for metabolic syndrome, ... edition of Daily Mail. ,These markers include raised ...
... (HPV) vaccine which is said to prevent about 75 percent ... and even women already exposed to the disease causing virus//, ... papillomavirus (HPV) has been approved for women aged 9 to ... and gynecology at the University of California-Irvine, argued that with ...
... 9,000 Danish residents revealed that a specific mutation in the ... breast cancer in her lifetime. The study, which was the ... the cancer risk associated with it, in the general population, ... Journal of Clinical Oncology. ,"Our study shows ...
... stop overdoses in heroin addicts. Hence many needle exchange ... news follows the deaths of at least 400 people ... ,Prevention Point Philadelphia, a nonprofit organization responsible for needle ... of naloxone prescriptions through a physician. "If people have ...
... the University of Florida, Gainesville, mice based experiments were found ... of the heart.// , This new technique was ... that damages the heart. The findings, published July 27 in ... studies in humans that could begin as soon as early ...
Cached Medicine News:Health News:Demand for More Widespread Use of HPV Vaccine 2Health News:Demand for More Widespread Use of HPV Vaccine 3Health News:CHEK 2 Gene Mutation Triples Breast Cancer Risk 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 3Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 4
IMMCO ANA Elisa meets the guidelines for the laboratory diagnosis and monitoring of systemic autoimmune rheumatic diseases intended for the use of clinical pathologists and laboratory physicians....
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
Medicine Products: